Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,951,041

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $884.50 -1.05 (-0.12%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs

Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.

Regeneron Gains on EUA Request for Coronavirus Treatment

Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), JPMorgan Chase (JPM) and Eli Lilly (LLY).

Company News for Oct 8, 2020

Companies in the news are: LLY, SUNW, SOL, KIN

Kinjel Shah headshot

Lilly Seeks Emergency Use of Coronavirus Antibody Candidate

Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.

David Bartosiak headshot

Best COVID Drug Stocks to Buy on Trump Recovery

Two of the best COVID drug stocks to buy became evident following President Trump's speedy recovery.

Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy

Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.

Sweta Killa headshot

4 Top ETFs, Stocks From Attractive Sectors Pre Q3 Earnings

We have highlighted one ETF and one stock from the four sectors that could make great plays as the earnings season unfolds.

Current Outlook Gloomy

Current Outlook Gloomy

Mark Vickery headshot

A Murky Way Forward, Plus Lilly's New Candidate

There is plenty to address in the coming weeks and months, though not much will be moving the needle this morning.

DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day

DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $146.63, marking a +0.98% move from the previous day.

Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive

The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Why Lilly (LLY) Could Beat Earnings Estimates Again

Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - October 01, 2020

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

3 Reasons Growth Investors Will Love Lilly (LLY)

Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication

Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $148.10 in the latest trading session, marking a -1.44% move from the prior day.

Gilead & Galapagos' RA Drug Receives Approval in Europe

Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.

Galapagos Gets First Commercial Drug With Jyseleca Approval

Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.

Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan

Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.

Sanghamitra Saha headshot

4 Reasons to Bet on Small-Cap ETFs Now

Small-cap stocks were hurt badly during the peak of the coronavirus-led lockdowns. Now, the gradual uptick of reopening trade has started to favor the small-cap spectrum.